Track ABIVAX Societe Anonyme — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ABIVAX Societe Anonyme AAVXF · Stock Open ABIVAX Societe Anonyme in new tab

139.00 USD
Add to portfolio
EPS
-3.67
P/B
4.86
ROE
-145.41
Beta
1.46
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateSept. 21, 2026
EPS-3.67
Book Value3.12
Price to Book4.86
Debt/Equity37.99
% Insiders1.875%
Growth
Revenue Growth0.00%

DCF Valuation

Tweak assumptions to recompute fair value for ABIVAX Societe Anonyme (AAVXF)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

ABIVAX Societe Anonyme Logo ABIVAX Societe Anonyme Analysis (AAVXF)

France Health Care Official Website Stock

Is ABIVAX Societe Anonyme a good investment? ABIVAX Societe Anonyme (AAVXF) is currently trading at 139.00 USD.

Earnings Schedule: ABIVAX Societe Anonyme is expected to release its next earnings report on Sept. 21, 2026.

Investor FAQ

Does ABIVAX Societe Anonyme pay a dividend?

No, it does not currently pay a dividend.

What asset class is ABIVAX Societe Anonyme?

ABIVAX Societe Anonyme is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Sept. 21, 2026. The company currently has a trailing EPS of -3.67.

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Exchange Ticker
PNK (United States) AAVXF
NASDAQ ABVX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion